Search results
Showing 196 to 210 of 1426 results for primary care
In development Reference number: GID-TA11502 Expected publication date: 02 December 2026
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]
In development Reference number: GID-TA11742 Expected publication date: 05 August 2026
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.
In development Reference number: GID-TA11635 Expected publication date: 26 August 2026
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development Reference number: GID-TA11333 Expected publication date: TBC
In development Reference number: GID-TA11566 Expected publication date: TBC
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
This guideline covers a set of principles that can be used to help people change their behaviour. The aim is for practitioners to use these principles to encourage people to adopt a healthier lifestyle by, for example, stopping smoking, adopting a healthy diet and being more physically active.
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
In development Reference number: GID-TA11819 Expected publication date: 03 September 2026
This quality standard covers preventing unintentional injury in children and young people (under 15). It includes local coordination of prevention strategies, and advice and assessment to help prevent accidents in the home. It describes high-quality care in priority areas for improvement.
View quality statements for QS107Show all sections
Sections for QS107
- Quality statements
- Quality statement 1: Coordinating action to prevent unintentional injuries
- Quality statement 2: Identifying households for a structured home safety assessment
- Quality statement 3: Structured home safety assessment
- Quality statement 4: Follow-up actions
- Quality statement 5: Integrating home safety into other visits
- About this quality standard
This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.
View quality statements for QS41Show all sections
Sections for QS41
- Quality statements
- Quality statement 1: Diagnosis
- Quality statement 2: Specialist referral
- Quality statement 3: DNA testing
- Quality statement 4: Diagnosis in children under 10 years
- Quality statement 5: Cascade testing
- Quality statement 6: Drug treatment in adults
- Quality statement 7: Drug treatment in children